Going acellular: an interview with Organicell

Written by RegMedNet

Mari Mitrani, Chief Science Officer, and Michael A. Bellio, Laboratory Director, Organicell (Miami, FL, USA), discuss the progression in cell therapeutics to the nanoscale for improved outcomes after stem cell transplantation in this exclusive interview. What are the benefits of acellular therapies vs cell-based therapies? There has been varied success of cell therapies, such as mesenchymal stem cell (MSC) therapies. One of the reasons for this variation is the degree of cell engraftment that occurs after transplantation. In finding limited cell engraftment after transplantation in cell therapies, questions were raised about the mechanism of action for the observed therapeutic effect...

To view the full article, please register now for access

It's completely free